Search

Displaying results 441 - 450 of 5876 in total
  1. Drug

    Garetosmab

    go.drugbank.com/drugs/DB16379
    ApprovedInvestigational

    Garetosmab-grts is an activin A inhibitor used to treat fibrodysplasia ossificans progressiva (FOP). … [L63940] Garetosmab-grts was approved by the FDA on August 19, 2026 to reduce the number of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP.

  2. Drug

    Levomefolic acid

    go.drugbank.com/drugs/DB11256
    Approved

    Supplementation of levomefolic acid is desired over folic acid due to reduced potential for masking vitamin B12 deficiency symptoms.

    Mixtures: Obtrex One, Obstetrix ONE
  3. Drug

    Liraglutide

    go.drugbank.com/drugs/DB06655
    ApprovedInvestigational

    [Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34.

  4. Drug

    Padimate O

    go.drugbank.com/drugs/DB11570
    Approved

    It is a structurally-related compound to [DB02362] that absorbs UV-B rays to prevent photodamage. … Padimate O is an active sunscreen agent in cosmetics and over-the-counter sunscreen drug products in concentrations up to 8%, as regulated by the FDA [L2153].

    Synonyms: Padimate O, Padimate-OMixtures: Care One Cherry SPF 4 Lip Balm, Care One Original SPF 4 Lip Balm
  5. Drug

    Medium-chain triglycerides

    go.drugbank.com/drugs/DB13959
    ApprovedInvestigational

    In the body, MCTs are broken down into glycerol and free fatty acids, which are directly absorbed into the blood stream and transported to the target organs to exert a range of biological and metabolic … Medium-chain triglycerides (MCTs) are triglycerides made up of a glycerol backbone and three fatty acids with an aliphatic tail of six to 12 carbon atoms.

    Mixtures: Nutriflex Lipid special ohne Elektrolyte Emulsion zur Infusion, Nutriflex Omega special ohne Elektrolyte B. Braun Emulsion zur Infusion
  6. Drug

    Phentermine

    go.drugbank.com/drugs/DB00191
    ApprovedIllicitInvestigational

    [A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. … [A174370] Phentermine has not been reported an addictive potential which allows this agent to be classified under the Schedule IV drugs (low abuse potential).

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    Concizumab therefore provides an important treatment option for patients who have developed inhibitors to standard clotting factor replacement therapy. … [L52043] One disadvantage of this approach is the possible development of antibodies (inhibitors) towards the administered replacement factor, rendering them less effective and increasing the likelihood

  8. Drug

    Yellow fever vaccine

    go.drugbank.com/drugs/DB10805
    ApprovedInvestigational

    The FDA recommends vaccination with Yellow Fever Vaccine for persons living in or travelling to endemic areas and for laboratory personnel who handle virulent yellow fever virus or concentrated preparations … It is composed of two live, attenuated strains of yellow fever virus, 17D-204 and 17DD, which have been shown to elicit an immune response identical to that induced by wild-type infection [FDA Label, A32118

  9. Drug

    Acarbose

    go.drugbank.com/drugs/DB00284
    ApprovedInvestigational

    [L31628,L31633] Acarbose is one of only two approved alpha-glucosidase inhibitors (the other being [miglitol]), receiving its first FDA approval in 1995 under the brand name Precose (since discontinued … [L31668] This class of antidiabetic therapy is not widely used due to their relatively modest impact on A1c, their requirement for thrice-daily dosing, and the potential for significant gastrointestinal

    Products: ACARBOSIO DOC GENERICI
  10. Drug

    Febuxostat

    go.drugbank.com/drugs/DB04854
    ApprovedInvestigational

    The manufacturer and the FDA advise health professionals to limit the use of febuxostat to second-line therapy in patients who have inadequate response or intolerance to allopurinol, and to avoid the use … [A230548] In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult patients with gout who have an inadequate response or intolerance to [allopurinol

    Products: FEBUXOSTAT GENEVIDA 80MG, FEBUXOSTAT DOC GENERICI